Labomed is delighted to announce that the European Patent Office has granted the European Patent EP3845215B1 covering the Lisdexamfetamine Oral Solution. The product has been developed by Labomed and sponsored by Labomed, Pharma-Data S.A. and Adalvo. This patent will provide the aforementioned parties protection to their value-added version of Lisdexamfetamine. The product comes in the form of a taste-masked, ready-to-use oral …

Labomed is delighted to announce that the European Patent Office has granted the European Patent EP3845215B1 Read More »

We are very proud to announce our strategic alliance with HELM AG on a worldwide basis in the co-development, registration, manufacture and commercialization of oral solution products, either generic versions of currently registered product or innovative ideas. This represents a huge milestone for Labomed that continues to create partnerships around the world, which will result …

Strategic alliance with HELM AG on a worldwide basis Read More »

Labomed S.A. is delighted to announce the completed and successful vaccination of its personnel.At Labomed, we have taken all the necessary actions that support Covid – 19 vaccine adoption.During this unprecedented healthcare crisis, our team has been encouraged and motivated to get vaccinated.Labomed adheres to all the appropriate state protocols against the Covid- 19 infection …

Labomed S.A. is delighted to announce the completed and successful vaccination of its personnel. Read More »

Labomed S.A is proud to announce the successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg/ml that has been co-sponsored & developed with Adalvo & Pharma-Data at our premises. We are moving ahead with the regulatory EU submission & US tech. transfer, whereby DCP slots have already been granted.This added value version of Lisdexamfetamine comes in the …

Labomed S.A is proud to announce the successful Pivotal BE outcome of Lisdexamfetamine Oral Solution Read More »